ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,395
0,00%
Bitcoin
69 381,91
0,07%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Arbutus Biopharma Corporation (ABUS)

  7. Arbutus Biopharma Corporation (ABUS) Actualités

ABUS Arbutus Biopharma Corporation

3,25
-0,09 (-2,69%)
08 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Arbutus Biopharma Corporation ABUS NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,09 -2,69% 3,25 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
3,31 3,12 3,31 3,20 3,34
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
06/6/202417:16EDGAR2Form 8-K - Current report
06/6/202417:15GLOBETreatment with Arbutus’ Imdusiran and VTP-300 Achieves..
05/6/202412:00EDGAR2Form 8-K - Current report
05/6/202408:30GLOBEArbutus’ Imdusiran with Short Course Interferon Achieves..
29/5/202413:30GLOBEArbutus to Participate in Jefferies Global Healthcare..
28/5/202422:25EDGAR2Form 8-K - Current report
24/5/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/5/202412:00EDGAR2Form 8-K - Current report
22/5/202408:00GLOBEArbutus to Present Imdusiran Data at EASL Congress 2024
17/5/202415:03EDGAR2Form SC 13D/A - General statement of acquisition of..
17/5/202415:00BWWhitefort Capital Publishes Open Letter to Arbutus Biopharma..
09/5/202414:00EDGAR2Form SC 13D - General statement of acquisition of beneficial..
07/5/202413:30GLOBEArbutus to Participate in Two Upcoming Investor Conferences
02/5/202413:30GLOBEArbutus Reports First Quarter 2024 Financial Results and..
02/5/202413:25GLOBEArbutus Announces Retirement of Chief Scientific Officer,..
18/4/202413:30GLOBEArbutus to Report First Quarter 2024 Financial Results and..
04/4/202414:30GLOBEArbutus Biopharma Announces Claim Construction Ruling in its..
08/3/202413:30GLOBEArbutus to Participate in Two Upcoming Investor Conferences
05/3/202422:48EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29/2/202413:31EDGAR2Form 8-K - Current report
29/2/202413:30GLOBEArbutus Reports Fourth Quarter and Year End 2023 Financial..
15/2/202413:30GLOBEArbutus to Report Fourth Quarter and Year End 2023 Financial..
14/2/202422:38EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202416:48EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202401:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202401:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202401:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202401:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202413:31EDGAR2Form 8-K - Current report
08/1/202413:30GLOBEArbutus Announces 2024 Corporate Objectives and Provides..
04/1/202422:09EDGAR2Form 8-K - Current report
21/11/202314:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
09/11/202322:02EDGAR2Form 8-K - Current report
08/11/202313:30GLOBEArbutus to Present at Jefferies London Healthcare Conference
07/11/202322:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202313:31EDGAR2Form 8-K - Current report
07/11/202313:30GLOBEArbutus Reports Third Quarter 2023 Financial Results and..
07/11/202313:16EDGAR2Form 8-K - Current report
07/11/202313:15GLOBEArbutus Announces CEO, William Collier, to Retire December..
24/10/202313:30GLOBEArbutus to Report Third Quarter 2023 Financial Results and..
18/10/202313:30GLOBEArbutus to Present at H.C. Wainwright 4th Annual Hepatitis B..
11/10/202314:06EDGAR2Form 8-K - Current report
11/10/202314:05GLOBEArbutus Announces Multiple Abstracts Accepted for..
11/9/202323:07EDGAR2Form SC 13G - Statement of acquisition of beneficial..
11/9/202322:16EDGAR2Form 8-K - Current report
11/9/202322:15GLOBEArbutus Announces Pipeline Updates and Dosing of the First..
07/9/202313:30GLOBEArbutus to Participate in Two Upcoming Investor Conferences
03/8/202322:18EDGAR2Form S-8 - Securities to be offered to employees in employee..
03/8/202322:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Dernières Valeurs Consultées

NASDAQ
ABUS
Arbutus Biopharma
LSE
FM39
Barclays 27
BIT
P21F12
NLBNPIT21F12 20240920 38...
BIT
P79984
BNP Paribas Issuance
EU
5756T
5756T
BIT
UC7WJE
Unicredit Bank
BIT
W0EEJ1
UBS
NYSE
CLP-D.CL
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés